JP6152643B2 - Ｉｌ−２３媒介疾患を治療するためのｅｐ４受容体拮抗薬の使用 - Google Patents
Ｉｌ−２３媒介疾患を治療するためのｅｐ４受容体拮抗薬の使用 Download PDFInfo
- Publication number
- JP6152643B2 JP6152643B2 JP2012538520A JP2012538520A JP6152643B2 JP 6152643 B2 JP6152643 B2 JP 6152643B2 JP 2012538520 A JP2012538520 A JP 2012538520A JP 2012538520 A JP2012538520 A JP 2012538520A JP 6152643 B2 JP6152643 B2 JP 6152643B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- ethyl
- amino
- alkyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 32
- 201000010099 disease Diseases 0.000 title claims description 29
- 230000001404 mediated effect Effects 0.000 title claims description 19
- 101150109738 Ptger4 gene Proteins 0.000 title description 20
- 239000002464 receptor antagonist Substances 0.000 title description 10
- 229940044551 receptor antagonist Drugs 0.000 title description 10
- -1 4- {2-Ethyl-4,6-dimethyl-1H-imidazo [4,5-c] pyridin-1-yl} phenyl Chemical group 0.000 claims description 214
- 150000001875 compounds Chemical class 0.000 claims description 112
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 49
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 37
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 30
- 239000004202 carbamide Substances 0.000 claims description 30
- 241000124008 Mammalia Species 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 26
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 13
- 206010012442 Dermatitis contact Diseases 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 201000004681 Psoriasis Diseases 0.000 claims description 11
- 208000002029 allergic contact dermatitis Diseases 0.000 claims description 11
- 230000003704 interleukin-23 production Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 5
- 241000208202 Linaceae Species 0.000 claims 1
- 235000004431 Linum usitatissimum Nutrition 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 description 177
- 125000000217 alkyl group Chemical group 0.000 description 172
- 125000005843 halogen group Chemical group 0.000 description 139
- 125000003118 aryl group Chemical group 0.000 description 110
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 97
- 125000003545 alkoxy group Chemical group 0.000 description 96
- 229910052757 nitrogen Inorganic materials 0.000 description 85
- 125000002950 monocyclic group Chemical group 0.000 description 77
- 125000004433 nitrogen atom Chemical group N* 0.000 description 64
- 125000004093 cyano group Chemical group *C#N 0.000 description 59
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 59
- 125000003277 amino group Chemical group 0.000 description 57
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 57
- 125000001424 substituent group Chemical group 0.000 description 57
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 53
- 125000004430 oxygen atom Chemical group O* 0.000 description 50
- 125000004434 sulfur atom Chemical group 0.000 description 50
- 125000005842 heteroatom Chemical group 0.000 description 37
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 37
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 36
- 125000002619 bicyclic group Chemical group 0.000 description 36
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 33
- 229910052717 sulfur Inorganic materials 0.000 description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- 206010020751 Hypersensitivity Diseases 0.000 description 28
- 125000001072 heteroaryl group Chemical group 0.000 description 28
- 230000007815 allergy Effects 0.000 description 26
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 24
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 24
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 description 22
- 125000002947 alkylene group Chemical group 0.000 description 22
- 125000004414 alkyl thio group Chemical group 0.000 description 21
- 208000026278 immune system disease Diseases 0.000 description 21
- 208000026935 allergic disease Diseases 0.000 description 20
- 125000000753 cycloalkyl group Chemical group 0.000 description 20
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 18
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 18
- 125000003342 alkenyl group Chemical group 0.000 description 18
- 125000001309 chloro group Chemical group Cl* 0.000 description 18
- 125000004043 oxo group Chemical group O=* 0.000 description 18
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 17
- 125000004076 pyridyl group Chemical group 0.000 description 17
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 17
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 16
- 125000005936 piperidyl group Chemical group 0.000 description 16
- 125000000335 thiazolyl group Chemical group 0.000 description 16
- 102100024450 Prostaglandin E2 receptor EP4 subtype Human genes 0.000 description 15
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 15
- 229910052799 carbon Inorganic materials 0.000 description 15
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- 231100000673 dose–response relationship Toxicity 0.000 description 13
- 125000003226 pyrazolyl group Chemical group 0.000 description 13
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 12
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- 208000023275 Autoimmune disease Diseases 0.000 description 11
- 125000002252 acyl group Chemical group 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 11
- 229910052801 chlorine Inorganic materials 0.000 description 11
- 125000001153 fluoro group Chemical group F* 0.000 description 11
- 125000001188 haloalkyl group Chemical group 0.000 description 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 125000005129 aryl carbonyl group Chemical group 0.000 description 10
- 125000001544 thienyl group Chemical group 0.000 description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 10
- 239000005711 Benzoic acid Substances 0.000 description 9
- 102000013691 Interleukin-17 Human genes 0.000 description 9
- 235000010233 benzoic acid Nutrition 0.000 description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 9
- 206010009887 colitis Diseases 0.000 description 9
- 125000004438 haloalkoxy group Chemical group 0.000 description 9
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 9
- 125000001113 thiadiazolyl group Chemical group 0.000 description 9
- 125000001589 carboacyl group Chemical group 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 8
- 125000002993 cycloalkylene group Chemical group 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 125000001624 naphthyl group Chemical group 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 8
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 7
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 7
- FKXDPPYCCKCVCW-LBPRGKRZSA-N 4-[(1s)-1-[[5-chloro-2-(3-fluorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=CC(F)=C1 FKXDPPYCCKCVCW-LBPRGKRZSA-N 0.000 description 7
- 210000000068 Th17 cell Anatomy 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 7
- 125000002971 oxazolyl group Chemical group 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- DOTIWNYTQPDMBR-ZDUSSCGKSA-N 4-[(1s)-1-[[2,5-dimethyl-4-[[4-(trifluoromethyl)phenyl]methyl]thiophene-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=C(C)SC(C)=C1CC1=CC=C(C(F)(F)F)C=C1 DOTIWNYTQPDMBR-ZDUSSCGKSA-N 0.000 description 6
- JJWCQIGUTYSYQF-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-[(3-chlorophenoxy)methyl]pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1COC1=CC=CC(Cl)=C1 JJWCQIGUTYSYQF-ZDUSSCGKSA-N 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 6
- 206010014025 Ear swelling Diseases 0.000 description 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 6
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- ZGFNLKCVKKEJKU-LBPRGKRZSA-N 4-[(1s)-1-[[5-chloro-2-(2,3-difluorophenoxy)benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1OC1=CC=CC(F)=C1F ZGFNLKCVKKEJKU-LBPRGKRZSA-N 0.000 description 5
- VKIBSGBBHPHLTP-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(2,3-difluorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=CC(F)=C1F VKIBSGBBHPHLTP-NSHDSACASA-N 0.000 description 5
- POCXSXWWUUVJIB-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(2-chloro-4-fluorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=C(F)C=C1Cl POCXSXWWUUVJIB-NSHDSACASA-N 0.000 description 5
- AMOAVOIZVZLGMJ-LBPRGKRZSA-N 4-[(1s)-1-[[5-chloro-2-(3,4-difluorophenoxy)benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1OC1=CC=C(F)C(F)=C1 AMOAVOIZVZLGMJ-LBPRGKRZSA-N 0.000 description 5
- NWAARQJHDWAZKA-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(3,4-difluorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=C(F)C(F)=C1 NWAARQJHDWAZKA-NSHDSACASA-N 0.000 description 5
- JDYZXLWEPUFOQR-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(3-chloro-5-fluorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC(F)=CC(Cl)=C1 JDYZXLWEPUFOQR-NSHDSACASA-N 0.000 description 5
- PSRWNAXGTLCGIF-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-(3-chlorophenoxy)benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1OC1=CC=CC(Cl)=C1 PSRWNAXGTLCGIF-ZDUSSCGKSA-N 0.000 description 5
- PAASJZUYDQEILO-LBPRGKRZSA-N 4-[(1s)-1-[[5-chloro-2-(3-chlorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=CC(Cl)=C1 PAASJZUYDQEILO-LBPRGKRZSA-N 0.000 description 5
- QEJPFCHVBBYBQL-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-(3-cyanophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=CC(C#N)=C1 QEJPFCHVBBYBQL-ZDUSSCGKSA-N 0.000 description 5
- KQRDIJJCEPLGDK-LBPRGKRZSA-N 4-[(1s)-1-[[5-chloro-2-(4-fluorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=C(F)C=C1 KQRDIJJCEPLGDK-LBPRGKRZSA-N 0.000 description 5
- IXDVRRPNWPOPGV-UHFFFAOYSA-N 4-[[4-(5-methoxypyridin-2-yl)phenoxy]methyl]-5-methyl-n-(2-methylphenyl)sulfonylfuran-2-carboxamide Chemical compound N1=CC(OC)=CC=C1C(C=C1)=CC=C1OCC1=C(C)OC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=C1 IXDVRRPNWPOPGV-UHFFFAOYSA-N 0.000 description 5
- MWBNCZHVEXULBD-ZDUSSCGKSA-N Benzoic acid, 4-[(1s)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]- Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1OC1=CC=C(F)C=C1 MWBNCZHVEXULBD-ZDUSSCGKSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 5
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 5
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 5
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 4
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 4
- BTXUOUJHLMYLQA-ZDUSSCGKSA-N 4-[(1s)-1-[[2-[(4-chlorophenoxy)methyl]-5-fluoropyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(F)=CN=C1COC1=CC=C(Cl)C=C1 BTXUOUJHLMYLQA-ZDUSSCGKSA-N 0.000 description 4
- HXOWIUWRSXNBNJ-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-(3-fluorophenoxy)benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1OC1=CC=CC(F)=C1 HXOWIUWRSXNBNJ-ZDUSSCGKSA-N 0.000 description 4
- ATOZZVAPMQDUSI-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-[(2,4-difluorophenoxy)methyl]benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1COC1=CC=C(F)C=C1F ATOZZVAPMQDUSI-ZDUSSCGKSA-N 0.000 description 4
- CFRRXXZVKGXOHU-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-[(3,5-difluorophenoxy)methyl]benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1COC1=CC(F)=CC(F)=C1 CFRRXXZVKGXOHU-ZDUSSCGKSA-N 0.000 description 4
- ATUADYJYXJTVGY-AWEZNQCLSA-N 4-[(1s)-1-[[5-chloro-2-[(3-chlorophenoxy)methyl]benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1COC1=CC=CC(Cl)=C1 ATUADYJYXJTVGY-AWEZNQCLSA-N 0.000 description 4
- IJIDEDSKWSQAIX-AWEZNQCLSA-N 4-[(1s)-1-[[5-chloro-2-[(3-fluorophenoxy)methyl]benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1COC1=CC=CC(F)=C1 IJIDEDSKWSQAIX-AWEZNQCLSA-N 0.000 description 4
- VXYYNZFXXXAZLQ-AWEZNQCLSA-N 4-[(1s)-1-[[5-chloro-2-[(4-chlorophenoxy)methyl]benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1COC1=CC=C(Cl)C=C1 VXYYNZFXXXAZLQ-AWEZNQCLSA-N 0.000 description 4
- RYTPCTBNJWUUHU-AWEZNQCLSA-N 4-[(1s)-1-[[5-chloro-2-[(4-fluorophenoxy)methyl]benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1COC1=CC=C(F)C=C1 RYTPCTBNJWUUHU-AWEZNQCLSA-N 0.000 description 4
- QJZQFVRFJCGDKF-UHFFFAOYSA-N 4-[1-[[2,5-dimethyl-4-[[4-(trifluoromethyl)phenyl]methyl]thiophene-3-carbonyl]amino]cyclopropyl]benzoic acid Chemical compound C=1C=C(C(F)(F)F)C=CC=1CC1=C(C)SC(C)=C1C(=O)NC1(C=2C=CC(=CC=2)C(O)=O)CC1 QJZQFVRFJCGDKF-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101100019396 Mus musculus Itgax gene Proteins 0.000 description 4
- 125000004103 aminoalkyl group Chemical group 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical group 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- SSDHSAQPLKZVRY-UHFFFAOYSA-N 1-(2-chlorophenyl)sulfonyl-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=CC=C1Cl SSDHSAQPLKZVRY-UHFFFAOYSA-N 0.000 description 3
- LRAMPOFRCGKEAQ-AWEZNQCLSA-N 2,5-dimethyl-n-[(1s)-1-[4-(methylsulfonylcarbamoyl)phenyl]ethyl]-4-[[4-(trifluoromethyl)phenyl]methyl]thiophene-3-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(=O)NS(C)(=O)=O)C(=O)C1=C(C)SC(C)=C1CC1=CC=C(C(F)(F)F)C=C1 LRAMPOFRCGKEAQ-AWEZNQCLSA-N 0.000 description 3
- CIEAOSWNZSOPSF-UHFFFAOYSA-N 2,5-dimethyl-n-[1-[4-(2h-tetrazol-5-yl)phenyl]cyclopropyl]-4-[[3-(trifluoromethyl)phenyl]methyl]thiophene-3-carboxamide Chemical compound C=1C=CC(C(F)(F)F)=CC=1CC1=C(C)SC(C)=C1C(=O)NC1(C=2C=CC(=CC=2)C2=NNN=N2)CC1 CIEAOSWNZSOPSF-UHFFFAOYSA-N 0.000 description 3
- FMLJGBDOSCBJBZ-UHFFFAOYSA-N 2,5-dimethyl-n-[1-[4-(2h-tetrazol-5-yl)phenyl]cyclopropyl]-4-[[4-(trifluoromethyl)phenyl]methyl]thiophene-3-carboxamide Chemical compound C=1C=C(C(F)(F)F)C=CC=1CC1=C(C)SC(C)=C1C(=O)NC1(C=2C=CC(=CC=2)C2=NNN=N2)CC1 FMLJGBDOSCBJBZ-UHFFFAOYSA-N 0.000 description 3
- YQUNVWHOTJLOLI-LLVKDONJSA-N 4-[(1r)-1-[[2,5-dichloro-4-[(3-chlorophenyl)methyl]thiophene-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=C(Cl)SC(Cl)=C1CC1=CC=CC(Cl)=C1 YQUNVWHOTJLOLI-LLVKDONJSA-N 0.000 description 3
- KMCFCSKMVIRYBI-NSHDSACASA-N 4-[(1s)-1-[[2,5-dibromo-4-[(3-chlorophenyl)methyl]thiophene-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=C(Br)SC(Br)=C1CC1=CC=CC(Cl)=C1 KMCFCSKMVIRYBI-NSHDSACASA-N 0.000 description 3
- WUZXHEDPFNIOGV-JTQLQIEISA-N 4-[(1s)-1-[[2,5-dichloro-4-(3-chlorobenzoyl)thiophene-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=C(Cl)SC(Cl)=C1C(=O)C1=CC=CC(Cl)=C1 WUZXHEDPFNIOGV-JTQLQIEISA-N 0.000 description 3
- UUZOSJJYPGRLFD-YGXOJQJDSA-N 4-[(1s)-1-[[2,5-dichloro-4-[(3-chlorophenyl)-(oxan-2-yloxy)methyl]thiophene-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=C(Cl)SC(Cl)=C1C(C=1C=C(Cl)C=CC=1)OC1CCCCO1 UUZOSJJYPGRLFD-YGXOJQJDSA-N 0.000 description 3
- YJEXRJWDVWQMEX-YOZOHBORSA-N 4-[(1s)-1-[[2,5-dichloro-4-[(3-chlorophenyl)-hydroxymethyl]thiophene-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=C(Cl)SC(Cl)=C1C(O)C1=CC=CC(Cl)=C1 YJEXRJWDVWQMEX-YOZOHBORSA-N 0.000 description 3
- YQUNVWHOTJLOLI-NSHDSACASA-N 4-[(1s)-1-[[2,5-dichloro-4-[(3-chlorophenyl)methyl]thiophene-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=C(Cl)SC(Cl)=C1CC1=CC=CC(Cl)=C1 YQUNVWHOTJLOLI-NSHDSACASA-N 0.000 description 3
- ASHWHAHRKQFQAR-NSHDSACASA-N 4-[(1s)-1-[[2,5-dichloro-4-[[3-(trifluoromethyl)phenyl]methyl]thiophene-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=C(Cl)SC(Cl)=C1CC1=CC=CC(C(F)(F)F)=C1 ASHWHAHRKQFQAR-NSHDSACASA-N 0.000 description 3
- DLMXCAVYRXOLRT-ZDUSSCGKSA-N 4-[(1s)-1-[[2,5-dimethyl-4-[[3-(trifluoromethyl)phenyl]methyl]thiophene-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=C(C)SC(C)=C1CC1=CC=CC(C(F)(F)F)=C1 DLMXCAVYRXOLRT-ZDUSSCGKSA-N 0.000 description 3
- YZTUSPHKCBTOSQ-ZDUSSCGKSA-N 4-[(1s)-1-[[4-[(3-chlorophenyl)methyl]-2,5-dimethylthiophene-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=C(C)SC(C)=C1CC1=CC=CC(Cl)=C1 YZTUSPHKCBTOSQ-ZDUSSCGKSA-N 0.000 description 3
- CKYFFWHUNIOYDH-ZDUSSCGKSA-N 4-[(1s)-1-[[4-[(3-chlorophenyl)methyl]thiophene-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CSC=C1CC1=CC=CC(Cl)=C1 CKYFFWHUNIOYDH-ZDUSSCGKSA-N 0.000 description 3
- FADNAZBPTQVMPQ-ZDUSSCGKSA-N 4-[(1s)-1-[[4-[(4-chlorophenyl)methyl]-2,5-dimethylthiophene-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=C(C)SC(C)=C1CC1=CC=C(Cl)C=C1 FADNAZBPTQVMPQ-ZDUSSCGKSA-N 0.000 description 3
- RZBIFXATYGZAHD-LBPRGKRZSA-N 4-[(1s)-1-[[5-bromo-4-[(3-chlorophenyl)methyl]thiophene-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CSC(Br)=C1CC1=CC=CC(Cl)=C1 RZBIFXATYGZAHD-LBPRGKRZSA-N 0.000 description 3
- XWIHFKIHPJOELR-INIZCTEOSA-N 4-[(1s)-1-[[5-chloro-2-(cyclohexylmethoxymethyl)benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1COCC1CCCCC1 XWIHFKIHPJOELR-INIZCTEOSA-N 0.000 description 3
- FFFKIGGQAODEPS-UHFFFAOYSA-N 4-[1-[[2,5-dimethyl-4-[[3-(trifluoromethyl)phenyl]methyl]thiophene-3-carbonyl]amino]cyclopropyl]benzoic acid Chemical compound C=1C=CC(C(F)(F)F)=CC=1CC1=C(C)SC(C)=C1C(=O)NC1(C=2C=CC(=CC=2)C(O)=O)CC1 FFFKIGGQAODEPS-UHFFFAOYSA-N 0.000 description 3
- NCZZPAVJNDIVAY-UHFFFAOYSA-N 4-[1-[[5-chloro-3-[(3-chlorophenyl)methyl]thiophene-2-carbonyl]amino]ethyl]benzoic acid Chemical compound C=1C=C(C(O)=O)C=CC=1C(C)NC(=O)C=1SC(Cl)=CC=1CC1=CC=CC(Cl)=C1 NCZZPAVJNDIVAY-UHFFFAOYSA-N 0.000 description 3
- BGASCMMYJZPCSS-UHFFFAOYSA-N 4-[[[2,5-dichloro-4-[(3-chlorophenyl)methyl]thiophene-3-carbonyl]amino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CNC(=O)C1=C(Cl)SC(Cl)=C1CC1=CC=CC(Cl)=C1 BGASCMMYJZPCSS-UHFFFAOYSA-N 0.000 description 3
- 125000006618 5- to 10-membered aromatic heterocyclic group Chemical group 0.000 description 3
- PYWZJCKVQWUVPO-UHFFFAOYSA-N 5-chloro-3-[(3-chlorophenyl)methyl]-n-[1-[4-(2h-tetrazol-5-yl)phenyl]ethyl]thiophene-2-carboxamide Chemical compound C=1C=C(C=2NN=NN=2)C=CC=1C(C)NC(=O)C=1SC(Cl)=CC=1CC1=CC=CC(Cl)=C1 PYWZJCKVQWUVPO-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 210000000447 Th1 cell Anatomy 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000004849 alkoxymethyl group Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 3
- 208000010247 contact dermatitis Diseases 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- ZAILXIKGMGZJPJ-SFHVURJKSA-N n-[(1s)-1-[4-(benzenesulfonylcarbamoyl)phenyl]ethyl]-2,5-dimethyl-4-[[4-(trifluoromethyl)phenyl]methyl]thiophene-3-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(=O)NS(=O)(=O)C=1C=CC=CC=1)C(=O)C1=C(C)SC(C)=C1CC1=CC=C(C(F)(F)F)C=C1 ZAILXIKGMGZJPJ-SFHVURJKSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 2
- XSQBHPPAOXQETA-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-4,5-dimethylbenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=C(C)C(C)=CC=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 XSQBHPPAOXQETA-UHFFFAOYSA-N 0.000 description 2
- HZVLFTCYCLXTGV-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=C(C)N=C(C)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 HZVLFTCYCLXTGV-UHFFFAOYSA-N 0.000 description 2
- DHQNPIRWIIQAKM-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-5,6-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC(C)=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 DHQNPIRWIIQAKM-UHFFFAOYSA-N 0.000 description 2
- GZFUZUFRJAEXPD-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-thiophen-2-ylsulfonylurea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=CS1 GZFUZUFRJAEXPD-UHFFFAOYSA-N 0.000 description 2
- MQBXOQQOCIUETP-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-5-hydroxybenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC(O)=CC=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 MQBXOQQOCIUETP-UHFFFAOYSA-N 0.000 description 2
- OZTHHJWONRMDRZ-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-6-methoxybenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC=C(OC)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 OZTHHJWONRMDRZ-UHFFFAOYSA-N 0.000 description 2
- RKBRFPVIJVMSEM-UHFFFAOYSA-N 1-[2-[4-(5,6-dichloro-2-ethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC(Cl)=C(Cl)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 RKBRFPVIJVMSEM-UHFFFAOYSA-N 0.000 description 2
- QGRORJBNJHUPRK-UHFFFAOYSA-N 1-[2-[4-(5-cyano-2-ethylbenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC(C#N)=CC=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 QGRORJBNJHUPRK-UHFFFAOYSA-N 0.000 description 2
- RXUWRKNOUPUCNP-UHFFFAOYSA-N 1-[2-[4-(6-acetyl-2-ethylbenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC=C(C(C)=O)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 RXUWRKNOUPUCNP-UHFFFAOYSA-N 0.000 description 2
- YDZNQEMQWNXSGF-UHFFFAOYSA-N 1-[2-[4-(6-chloro-2-ethyl-5-methylsulfonylbenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC(S(C)(=O)=O)=C(Cl)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 YDZNQEMQWNXSGF-UHFFFAOYSA-N 0.000 description 2
- FIXXXBYFTUXZLG-UHFFFAOYSA-N 1-[2-[4-(6-ethyl-[1,3]dioxolo[4,5-f]benzimidazol-7-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC=3OCOC=3C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 FIXXXBYFTUXZLG-UHFFFAOYSA-N 0.000 description 2
- GFMMZVFKQDQZHJ-UHFFFAOYSA-N 1-[2-[4-[2-ethyl-5-(2-hydroxypropan-2-yl)benzimidazol-1-yl]phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC(C(C)(C)O)=CC=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 GFMMZVFKQDQZHJ-UHFFFAOYSA-N 0.000 description 2
- JEJBRXQXDMSKME-UHFFFAOYSA-N 1-[2-[4-[5,7-dimethyl-2-(1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-3-yl]phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NCCC1=CC=C(N2C3=NC(C)=CC(C)=C3N=C2C2=NNC=C2)C=C1 JEJBRXQXDMSKME-UHFFFAOYSA-N 0.000 description 2
- ZVHXCMFIZUHPFN-UHFFFAOYSA-N 1-[2-[4-[5,7-dimethyl-2-(methylamino)imidazo[4,5-b]pyridin-3-yl]phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CNC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 ZVHXCMFIZUHPFN-UHFFFAOYSA-N 0.000 description 2
- UEXRPEOZBKYETI-UHFFFAOYSA-N 1-[2-[4-[5,7-dimethyl-2-[2-(1,3-thiazol-2-yl)ethyl]imidazo[4,5-b]pyridin-3-yl]phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NCCC1=CC=C(N2C3=NC(C)=CC(C)=C3N=C2CCC=2SC=CN=2)C=C1 UEXRPEOZBKYETI-UHFFFAOYSA-N 0.000 description 2
- ITZFODVISQIQFV-UHFFFAOYSA-N 1-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]propan-2-yl n-(4-methylphenyl)sulfonylcarbamate Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CC(C)OC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 ITZFODVISQIQFV-UHFFFAOYSA-N 0.000 description 2
- QMHYCEZPVUGVHC-UHFFFAOYSA-N 2-[4-(2-butyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl n-(4-methylphenyl)sulfonylcarbamate Chemical compound CCCCC1=NC2=C(C)N=C(C)C=C2N1C(C=C1)=CC=C1CCOC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 QMHYCEZPVUGVHC-UHFFFAOYSA-N 0.000 description 2
- MOBSEOODRXRKSY-UHFFFAOYSA-N 2-ethyl-4,6-dimethyl-1-[4-[2-[(4-methylphenyl)sulfonylcarbamoylamino]ethyl]phenyl]benzimidazole-5-carboxamide Chemical compound CCC1=NC2=C(C)C(C(N)=O)=C(C)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 MOBSEOODRXRKSY-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- YPTHWKLHJGBLPK-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(2,3-dichlorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=CC(Cl)=C1Cl YPTHWKLHJGBLPK-NSHDSACASA-N 0.000 description 2
- WMDQZTNZXDPFDN-LBPRGKRZSA-N 4-[(1s)-1-[[5-chloro-2-(2,5-difluorophenoxy)benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1OC1=CC(F)=CC=C1F WMDQZTNZXDPFDN-LBPRGKRZSA-N 0.000 description 2
- VEOFQJJMHQFJCU-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(2,5-difluorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC(F)=CC=C1F VEOFQJJMHQFJCU-NSHDSACASA-N 0.000 description 2
- OABBIWZKQQRFNA-LBPRGKRZSA-N 4-[(1s)-1-[[5-chloro-2-(2,6-difluorophenoxy)benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1OC1=C(F)C=CC=C1F OABBIWZKQQRFNA-LBPRGKRZSA-N 0.000 description 2
- RCTVPEUEZURVAL-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(2,6-difluorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=C(F)C=CC=C1F RCTVPEUEZURVAL-NSHDSACASA-N 0.000 description 2
- YWMHIFDHUSWUPQ-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(2-chloro-5-fluorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC(F)=CC=C1Cl YWMHIFDHUSWUPQ-NSHDSACASA-N 0.000 description 2
- MXUQJWKBNVDIGU-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(3,4-dichlorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=C(Cl)C(Cl)=C1 MXUQJWKBNVDIGU-NSHDSACASA-N 0.000 description 2
- FCGPTSVPTMARLR-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(3,5-dichlorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC(Cl)=CC(Cl)=C1 FCGPTSVPTMARLR-NSHDSACASA-N 0.000 description 2
- XAJIBCVYDLMFFP-LBPRGKRZSA-N 4-[(1s)-1-[[5-chloro-2-(3,5-difluorophenoxy)benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1OC1=CC(F)=CC(F)=C1 XAJIBCVYDLMFFP-LBPRGKRZSA-N 0.000 description 2
- DFIPXHHBUZAAEU-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(3,5-difluorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC(F)=CC(F)=C1 DFIPXHHBUZAAEU-NSHDSACASA-N 0.000 description 2
- XNXBJOBGRSVMTK-LBPRGKRZSA-N 4-[(1s)-1-[[5-chloro-2-(3-chloro-5-fluorophenoxy)benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1OC1=CC(F)=CC(Cl)=C1 XNXBJOBGRSVMTK-LBPRGKRZSA-N 0.000 description 2
- ACFXHKRTFYNQPW-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-(3-chloro-5-methylphenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC(C)=CC(Cl)=C1 ACFXHKRTFYNQPW-ZDUSSCGKSA-N 0.000 description 2
- ZGUZHAIQRCPMTK-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-(3-fluoro-4-methylphenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=C(C)C(F)=C1 ZGUZHAIQRCPMTK-ZDUSSCGKSA-N 0.000 description 2
- PHKYEQDBKJKLES-HNNXBMFYSA-N 4-[(1s)-1-[[5-chloro-2-(3-methylphenoxy)benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1OC1=CC=CC(C)=C1 PHKYEQDBKJKLES-HNNXBMFYSA-N 0.000 description 2
- VDYXVRZMLYFTSE-AWEZNQCLSA-N 4-[(1s)-1-[[5-chloro-2-(3-methylphenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=CC(C)=C1 VDYXVRZMLYFTSE-AWEZNQCLSA-N 0.000 description 2
- KYKVWMBQMHXMLJ-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-[(3,4-difluorophenoxy)methyl]benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1COC1=CC=C(F)C(F)=C1 KYKVWMBQMHXMLJ-ZDUSSCGKSA-N 0.000 description 2
- 125000006418 4-methylphenylsulfonyl group Chemical group 0.000 description 2
- WLKMZINZFGUOBX-UHFFFAOYSA-N 6-chloro-2-ethyl-1-[4-[2-[(4-methylphenyl)sulfonylcarbamoylamino]ethyl]phenyl]benzimidazole-5-carboxamide Chemical compound CCC1=NC2=CC(C(N)=O)=C(Cl)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 WLKMZINZFGUOBX-UHFFFAOYSA-N 0.000 description 2
- AJZMANQISJQJQM-UHFFFAOYSA-N 6-chloro-2-ethyl-1-[4-[2-[methyl-[(4-methylphenyl)sulfonylcarbamoyl]amino]ethyl]phenyl]benzimidazole-5-carboxamide Chemical compound CCC1=NC2=CC(C(N)=O)=C(Cl)C=C2N1C(C=C1)=CC=C1CCN(C)C(=O)NS(=O)(=O)C1=CC=C(C)C=C1 AJZMANQISJQJQM-UHFFFAOYSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000024781 Immune Complex disease Diseases 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100035842 Prostaglandin E2 receptor EP1 subtype Human genes 0.000 description 2
- 102100024448 Prostaglandin E2 receptor EP2 subtype Human genes 0.000 description 2
- 102100024447 Prostaglandin E2 receptor EP3 subtype Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000001091 aminosulfinyl group Chemical group [H]N([H])S(*)=O 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GDMPUWXHOZINFC-UHFFFAOYSA-N (4-methylphenyl) n-sulfonylcarbamate Chemical compound CC1=CC=C(OC(=O)N=S(=O)=O)C=C1 GDMPUWXHOZINFC-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- DJCKGBKRWDFMCI-UHFFFAOYSA-N 1-(1-benzothiophen-2-ylsulfonyl)-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound C1=CC=C2SC(S(=O)(=O)NC(=O)NCCC3=CC=C(C=C3)N3C4=NC(C)=CC(C)=C4N=C3CC)=CC2=C1 DJCKGBKRWDFMCI-UHFFFAOYSA-N 0.000 description 1
- CMTOMNMETHIQAO-UHFFFAOYSA-N 1-(2-bromophenyl)sulfonyl-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=CC=C1Br CMTOMNMETHIQAO-UHFFFAOYSA-N 0.000 description 1
- OJIFDBSNXCGHBQ-UHFFFAOYSA-N 1-(3-chlorophenyl)sulfonyl-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=CC(Cl)=C1 OJIFDBSNXCGHBQ-UHFFFAOYSA-N 0.000 description 1
- DYVSMRWSEWJQNX-UHFFFAOYSA-N 1-(4,5-dichlorothiophen-2-yl)sulfonyl-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC(Cl)=C(Cl)S1 DYVSMRWSEWJQNX-UHFFFAOYSA-N 0.000 description 1
- XCVHOHHHDQCOBD-UHFFFAOYSA-N 1-(4-chloro-3-nitrophenyl)sulfonyl-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 XCVHOHHHDQCOBD-UHFFFAOYSA-N 0.000 description 1
- ITYQCVLIFYKIKM-UHFFFAOYSA-N 1-(4-chlorophenyl)sulfonyl-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 ITYQCVLIFYKIKM-UHFFFAOYSA-N 0.000 description 1
- RRUHFXQQVRXDCL-UHFFFAOYSA-N 1-[(2,4-dimethyl-1,3-thiazol-5-yl)sulfonyl]-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C=1SC(C)=NC=1C RRUHFXQQVRXDCL-UHFFFAOYSA-N 0.000 description 1
- XATLZQAKLWPMPH-UHFFFAOYSA-N 1-[1-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]propan-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CC(C)NC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 XATLZQAKLWPMPH-UHFFFAOYSA-N 0.000 description 1
- LZRDBVMHYJZYKK-UHFFFAOYSA-N 1-[2-[4-(2-butyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCCCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 LZRDBVMHYJZYKK-UHFFFAOYSA-N 0.000 description 1
- KWCIFZJRSKOLIK-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-5,7-dimethylbenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC(C)=CC(C)=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 KWCIFZJRSKOLIK-UHFFFAOYSA-N 0.000 description 1
- IBFDKPDVDWAFLS-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-1-methyl-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCN(C)C(=O)NS(=O)(=O)C1=CC=C(C)C=C1 IBFDKPDVDWAFLS-UHFFFAOYSA-N 0.000 description 1
- UBBBCBCWMHKSKB-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-(4-phenylphenyl)sulfonylurea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C(C=C1)=CC=C1C1=CC=CC=C1 UBBBCBCWMHKSKB-UHFFFAOYSA-N 0.000 description 1
- DCVOMGDWHZCNLH-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-naphthalen-1-ylsulfonylurea Chemical compound C1=CC=C2C(S(=O)(=O)NC(=O)NCCC3=CC=C(C=C3)N3C4=NC(C)=CC(C)=C4N=C3CC)=CC=CC2=C1 DCVOMGDWHZCNLH-UHFFFAOYSA-N 0.000 description 1
- GPYDLTMRLWLKHM-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-naphthalen-2-ylsulfonylurea Chemical compound C1=CC=CC2=CC(S(=O)(=O)NC(=O)NCCC3=CC=C(C=C3)N3C4=NC(C)=CC(C)=C4N=C3CC)=CC=C21 GPYDLTMRLWLKHM-UHFFFAOYSA-N 0.000 description 1
- PUETWJKTSRUGDU-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-7-methylbenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC=CC(C)=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 PUETWJKTSRUGDU-UHFFFAOYSA-N 0.000 description 1
- WPMBBXBTXCWNCZ-UHFFFAOYSA-N 1-[2-[4-(4-chloro-2-ethylbenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=C(Cl)C=CC=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 WPMBBXBTXCWNCZ-UHFFFAOYSA-N 0.000 description 1
- CBFFANHNQPPLPD-UHFFFAOYSA-N 1-[2-[4-(5,6-dichloro-2-ethylbenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC(Cl)=C(Cl)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 CBFFANHNQPPLPD-UHFFFAOYSA-N 0.000 description 1
- JGZXIXATYHJSAV-UHFFFAOYSA-N 1-[2-[4-(5,6-dimethylbenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NCCC1=CC=C(N2C3=CC(C)=C(C)C=C3N=C2)C=C1 JGZXIXATYHJSAV-UHFFFAOYSA-N 0.000 description 1
- UIVUAFGBAGUAHH-UHFFFAOYSA-N 1-[2-[4-(5,7-dimethyl-2-propan-2-ylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CC(C)C1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 UIVUAFGBAGUAHH-UHFFFAOYSA-N 0.000 description 1
- DNQWLTCEJSXBGE-UHFFFAOYSA-N 1-[2-[4-(5,7-dimethyl-2-propylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 DNQWLTCEJSXBGE-UHFFFAOYSA-N 0.000 description 1
- PJBCMGNUMXMKAS-UHFFFAOYSA-N 1-[2-[4-(5-chloro-2-ethyl-7-methylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=C(C)C=C(Cl)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 PJBCMGNUMXMKAS-UHFFFAOYSA-N 0.000 description 1
- RSXKMRPPWWLXMI-UHFFFAOYSA-N 1-[2-[4-(5-chloro-6-methylbenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NCCC1=CC=C(N2C3=CC(C)=C(Cl)C=C3N=C2)C=C1 RSXKMRPPWWLXMI-UHFFFAOYSA-N 0.000 description 1
- DNIARSNMMRQNKE-UHFFFAOYSA-N 1-[2-[4-(6-cyano-2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=C(C)C(C#N)=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 DNIARSNMMRQNKE-UHFFFAOYSA-N 0.000 description 1
- JRFBMPZMVMJMNA-UHFFFAOYSA-N 1-[2-[4-[2-(2,2-dimethylpropyl)-5,7-dimethylimidazo[4,5-b]pyridin-3-yl]phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NCCC1=CC=C(N2C3=NC(C)=CC(C)=C3N=C2CC(C)(C)C)C=C1 JRFBMPZMVMJMNA-UHFFFAOYSA-N 0.000 description 1
- GQGGVKWIQFESMF-UHFFFAOYSA-N 1-[2-[4-[5,7-dimethyl-2-(2-methylpropyl)imidazo[4,5-b]pyridin-3-yl]phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CC(C)CC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 GQGGVKWIQFESMF-UHFFFAOYSA-N 0.000 description 1
- JKPPWQNNVYZCJS-UHFFFAOYSA-N 1-[2-[4-[6-chloro-5-(trifluoromethyl)benzimidazol-1-yl]phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NCCC1=CC=C(N2C3=CC(Cl)=C(C=C3N=C2)C(F)(F)F)C=C1 JKPPWQNNVYZCJS-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- SDRALVQCLJHHOR-UHFFFAOYSA-N 2-chloro-1,3,5-trinitrobenzene;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1 SDRALVQCLJHHOR-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- YCMLQMDWSXFTIF-UHFFFAOYSA-N 2-methylbenzenesulfonimidic acid Chemical compound CC1=CC=CC=C1S(N)(=O)=O YCMLQMDWSXFTIF-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- YXFXSKVEOJIGTI-ZDUSSCGKSA-N 4-[(1s)-1-[(5-chloro-2-phenoxypyridine-3-carbonyl)amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=CC=C1 YXFXSKVEOJIGTI-ZDUSSCGKSA-N 0.000 description 1
- DWIRELABWMXKGB-HNNXBMFYSA-N 4-[(1s)-1-[[5-chloro-2-(2,3-dimethylphenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=CC(C)=C1C DWIRELABWMXKGB-HNNXBMFYSA-N 0.000 description 1
- ABGNRFBWYDDSFY-LBPRGKRZSA-N 4-[(1s)-1-[[5-chloro-2-(2,4-difluorophenoxy)benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1OC1=CC=C(F)C=C1F ABGNRFBWYDDSFY-LBPRGKRZSA-N 0.000 description 1
- SSYRJHYGPQMIGM-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(2,4-difluorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=C(F)C=C1F SSYRJHYGPQMIGM-NSHDSACASA-N 0.000 description 1
- FJSCRBCUUXNNFG-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(3-chloro-2-fluorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=CC(Cl)=C1F FJSCRBCUUXNNFG-NSHDSACASA-N 0.000 description 1
- XRMGJOKLRKBGCH-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-(3-chloro-2-methylphenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=CC(Cl)=C1C XRMGJOKLRKBGCH-ZDUSSCGKSA-N 0.000 description 1
- YBZZHIGZUMDLOL-INIZCTEOSA-N 4-[(1s)-1-[[5-chloro-2-(3-pyridin-2-ylphenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC(C=1)=CC=CC=1C1=CC=CC=N1 YBZZHIGZUMDLOL-INIZCTEOSA-N 0.000 description 1
- CWXXTWZDKKOBPW-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(4-chloro-2-fluorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=C(Cl)C=C1F CWXXTWZDKKOBPW-NSHDSACASA-N 0.000 description 1
- JLGWLTOXEHYMSV-NSHDSACASA-N 4-[(1s)-1-[[5-chloro-2-(4-chloro-3-fluorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=C(Cl)C(F)=C1 JLGWLTOXEHYMSV-NSHDSACASA-N 0.000 description 1
- RWFZXCCXWCQLBQ-LBPRGKRZSA-N 4-[(1s)-1-[[5-chloro-2-(4-chlorophenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=C(Cl)C=C1 RWFZXCCXWCQLBQ-LBPRGKRZSA-N 0.000 description 1
- XPEMIDUVSAAGJN-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-(4-fluoro-3-methylphenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC1=CC=C(F)C(C)=C1 XPEMIDUVSAAGJN-ZDUSSCGKSA-N 0.000 description 1
- RRRUSDRQYRJVJL-INIZCTEOSA-N 4-[(1s)-1-[[5-chloro-2-(4-pyridin-2-ylphenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC(C=C1)=CC=C1C1=CC=CC=N1 RRRUSDRQYRJVJL-INIZCTEOSA-N 0.000 description 1
- YNSVBIMYEBSPNZ-INIZCTEOSA-N 4-[(1s)-1-[[5-chloro-2-(4-pyridin-4-ylphenoxy)pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC(C=C1)=CC=C1C1=CC=NC=C1 YNSVBIMYEBSPNZ-INIZCTEOSA-N 0.000 description 1
- QRPQXHWSXCFMEC-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-[(2,3-difluorophenoxy)methyl]benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1COC1=CC=CC(F)=C1F QRPQXHWSXCFMEC-ZDUSSCGKSA-N 0.000 description 1
- SOVFEBNEMFTGDJ-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-[(2,5-difluorophenoxy)methyl]benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1COC1=CC(F)=CC=C1F SOVFEBNEMFTGDJ-ZDUSSCGKSA-N 0.000 description 1
- KMCGRMBZIGFFJO-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-[(2,6-difluorophenoxy)methyl]benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1COC1=C(F)C=CC=C1F KMCGRMBZIGFFJO-ZDUSSCGKSA-N 0.000 description 1
- HGDAPQIZHQIIPZ-AWEZNQCLSA-N 4-[(1s)-1-[[5-chloro-2-[(2-chlorophenoxy)methyl]benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1COC1=CC=CC=C1Cl HGDAPQIZHQIIPZ-AWEZNQCLSA-N 0.000 description 1
- PTBZKIYFZISXHX-AWEZNQCLSA-N 4-[(1s)-1-[[5-chloro-2-[(2-fluorophenoxy)methyl]benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1COC1=CC=CC=C1F PTBZKIYFZISXHX-AWEZNQCLSA-N 0.000 description 1
- JGECSXITSDIWOZ-ZDUSSCGKSA-N 4-[(1s)-1-[[5-chloro-2-[(4-chlorophenoxy)methyl]pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1COC1=CC=C(Cl)C=C1 JGECSXITSDIWOZ-ZDUSSCGKSA-N 0.000 description 1
- HNQRKSYCUAMFTB-INIZCTEOSA-N 4-[(1s)-1-[[5-chloro-2-[(4-methylphenoxy)methyl]benzoyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CC=C1COC1=CC=C(C)C=C1 HNQRKSYCUAMFTB-INIZCTEOSA-N 0.000 description 1
- ZFVOJMAHKWWRBR-AWEZNQCLSA-N 4-[(1s)-1-[[5-chloro-2-[3-(1,3-thiazol-2-yl)phenoxy]pyridine-3-carbonyl]amino]ethyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(O)=O)C(=O)C1=CC(Cl)=CN=C1OC(C=1)=CC=CC=1C1=NC=CS1 ZFVOJMAHKWWRBR-AWEZNQCLSA-N 0.000 description 1
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000282672 Ateles sp. Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000000209 Isaacs syndrome Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000288903 Lemuridae Species 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010072359 Neuromyotonia Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010040981 Sleep attacks Diseases 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 206010054000 Type II hypersensitivity Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004977 cycloheptylene group Chemical group 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- GZXKKIJHJNCWNH-UHFFFAOYSA-N n-[5-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethylcarbamoylsulfamoyl]-1,3,4-thiadiazol-2-yl]acetamide Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=NN=C(NC(C)=O)S1 GZXKKIJHJNCWNH-UHFFFAOYSA-N 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005767 propoxymethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])[#8]C([H])([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000006941 response to substance Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000008026 type II hypersensitivity Effects 0.000 description 1
- 230000028063 type III hypersensitivity Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28250610P | 2010-02-22 | 2010-02-22 | |
| US61/282,506 | 2010-02-22 | ||
| PCT/JP2011/000994 WO2011102149A1 (en) | 2010-02-22 | 2011-02-22 | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017013578A Division JP2017095511A (ja) | 2010-02-22 | 2017-01-27 | Ｉｌ−２３媒介疾患を治療するためのｅｐ４受容体拮抗薬の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013520397A JP2013520397A (ja) | 2013-06-06 |
| JP2013520397A5 JP2013520397A5 (cg-RX-API-DMAC7.html) | 2014-04-10 |
| JP6152643B2 true JP6152643B2 (ja) | 2017-06-28 |
Family
ID=44482754
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538520A Active JP6152643B2 (ja) | 2010-02-22 | 2011-02-22 | Ｉｌ−２３媒介疾患を治療するためのｅｐ４受容体拮抗薬の使用 |
| JP2017013578A Withdrawn JP2017095511A (ja) | 2010-02-22 | 2017-01-27 | Ｉｌ−２３媒介疾患を治療するためのｅｐ４受容体拮抗薬の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017013578A Withdrawn JP2017095511A (ja) | 2010-02-22 | 2017-01-27 | Ｉｌ−２３媒介疾患を治療するためのｅｐ４受容体拮抗薬の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9457084B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2538978B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6152643B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101780666B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN102770159A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012020236A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2789665C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2600355T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1249401A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX341482B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2571816C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011102149A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3296B1 (ar) | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| UA115576C2 (uk) * | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| SI3083562T1 (sl) | 2013-12-17 | 2017-11-30 | Eli Lilly And Company | Derivati fenoksietil cikličnih aminov in njihova aktivnost kot modulatorji EP4 receptorja |
| TW201607943A (zh) * | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| MX376175B (es) | 2014-03-06 | 2025-03-07 | Aratana Therapeutics Inc | Composiciones de grapiprant y metodos para usar las mismas. |
| US12109218B2 (en) | 2014-12-09 | 2024-10-08 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| CN108473497B (zh) * | 2015-10-16 | 2021-09-10 | 卫材R&D 管理有限公司 | Ep4拮抗剂 |
| US10342785B2 (en) * | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| MA55695A (fr) | 2017-01-23 | 2022-02-23 | Genentech Inc | Composés chimiques comme inhibiteurs de l'activité interleukine-1 |
| CN109836434B (zh) * | 2017-11-27 | 2020-09-25 | 上海宇耀生物科技有限公司 | 噻吩并环类化合物及其合成方法和应用 |
| CN112292128A (zh) | 2018-04-16 | 2021-01-29 | 阿瑞斯医疗有限公司 | Ep4抑制剂和其用途 |
| US10239885B1 (en) | 2018-06-18 | 2019-03-26 | Avista Pharma Solutions, Inc. | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2020018970A1 (en) | 2018-07-20 | 2020-01-23 | Genentech, Inc. | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| MX2021000780A (es) | 2018-07-20 | 2021-03-31 | Hoffmann La Roche | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1. |
| HUE066335T2 (hu) | 2018-10-05 | 2024-07-28 | Annapurna Bio Inc | Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére |
| WO2020160075A1 (en) | 2019-01-30 | 2020-08-06 | Avista Pharma Solutions, Inc. | Chemical compounds |
| MX2021009251A (es) | 2019-01-30 | 2021-09-21 | Avista Pharma Solutions Inc | Proceso de sintesis y nuevos compuestos intermedios. |
| CN115697317A (zh) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| IL164263A0 (en) | 2002-04-12 | 2005-12-18 | Pfizer | Use of ep4 receptor ligands on the treatment of il-6 involved diseases |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| DE602004013938D1 (de) * | 2003-01-29 | 2008-07-03 | Asterand Uk Ltd | Hemmstoffe des ep4-rezeptors |
| AU2004268839A1 (en) | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists |
| CN1946391A (zh) * | 2004-04-20 | 2007-04-11 | 辉瑞产品公司 | 包含α－2－δ配体的组合 |
| KR20070006891A (ko) | 2004-05-04 | 2007-01-11 | 화이자 인코포레이티드 | 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물 |
| ES2344310T3 (es) * | 2005-03-11 | 2010-08-24 | Raqualia Pharma Inc | Formas cristalinas de un derivado de imidazol. |
| EP1886987A1 (en) * | 2006-08-11 | 2008-02-13 | Givaudan S.A. | Process for producing 2,2,3-trimethylcyclopent-3-enecarbaldehyde (campholytic aldehyde) |
| JP5259592B2 (ja) * | 2006-08-11 | 2013-08-07 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
-
2011
- 2011-02-22 CA CA2789665A patent/CA2789665C/en active Active
- 2011-02-22 CA CA3009937A patent/CA3009937C/en active Active
- 2011-02-22 MX MX2012009503A patent/MX341482B/es active IP Right Grant
- 2011-02-22 EP EP11744440.6A patent/EP2538978B1/en active Active
- 2011-02-22 CN CN2011800104626A patent/CN102770159A/zh active Pending
- 2011-02-22 US US13/580,323 patent/US9457084B2/en active Active
- 2011-02-22 ES ES11744440.6T patent/ES2600355T3/es active Active
- 2011-02-22 KR KR1020127024115A patent/KR101780666B1/ko active Active
- 2011-02-22 RU RU2012140450/15A patent/RU2571816C2/ru active
- 2011-02-22 BR BR112012020236A patent/BR112012020236A2/pt not_active Application Discontinuation
- 2011-02-22 WO PCT/JP2011/000994 patent/WO2011102149A1/en not_active Ceased
- 2011-02-22 CN CN201711045618.XA patent/CN107693518A/zh active Pending
- 2011-02-22 JP JP2012538520A patent/JP6152643B2/ja active Active
-
2017
- 2017-01-27 JP JP2017013578A patent/JP2017095511A/ja not_active Withdrawn
-
2018
- 2018-06-15 HK HK18107808.7A patent/HK1249401A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2538978A4 (en) | 2013-10-16 |
| HK1249401A1 (zh) | 2018-11-02 |
| KR20130040787A (ko) | 2013-04-24 |
| RU2012140450A (ru) | 2014-03-27 |
| CA2789665C (en) | 2020-06-16 |
| EP2538978B1 (en) | 2016-09-07 |
| US20120316197A1 (en) | 2012-12-13 |
| MX341482B (es) | 2016-08-22 |
| BR112012020236A2 (pt) | 2016-05-17 |
| CA3009937A1 (en) | 2011-08-25 |
| CN102770159A (zh) | 2012-11-07 |
| MX2012009503A (es) | 2012-09-12 |
| CA2789665A1 (en) | 2011-08-25 |
| WO2011102149A1 (en) | 2011-08-25 |
| HK1178088A1 (zh) | 2013-09-06 |
| JP2017095511A (ja) | 2017-06-01 |
| EP2538978A1 (en) | 2013-01-02 |
| JP2013520397A (ja) | 2013-06-06 |
| KR101780666B1 (ko) | 2017-09-21 |
| RU2571816C2 (ru) | 2015-12-20 |
| ES2600355T3 (es) | 2017-02-08 |
| CN107693518A (zh) | 2018-02-16 |
| US9457084B2 (en) | 2016-10-04 |
| CA3009937C (en) | 2020-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6152643B2 (ja) | Ｉｌ−２３媒介疾患を治療するためのｅｐ４受容体拮抗薬の使用 | |
| JP6340702B2 (ja) | 軟骨疾患を治療するためのｅｐ４受容体拮抗薬の使用 | |
| WO2020259528A1 (zh) | 治疗特发性肺纤维化的方法 | |
| AU2007304439A1 (en) | Treatment for non-alcoholic-steatohepatitis | |
| US10391086B2 (en) | Use of EP4 receptor antagonists in the treatment of cartilage disease | |
| HK1177148A (en) | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases | |
| HK1212211B (zh) | Ep4受体拮抗剂在软骨疾病的治疗中的用途 | |
| WO2007010946A1 (ja) | 滑膜細胞増殖抑制剤 | |
| HK1178088B (en) | Use of an ep4 receptor antagonist in the treatment of allergic contact dermatitis and psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140218 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140218 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150423 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150908 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151208 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20151218 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20160205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170127 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20170515 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170515 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170517 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6152643 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |